Nucleai
About Nucleai
Nucleai is an AI-powered spatial biology company that aims to revolutionize cancer treatment and drug discovery by providing crucial context from tissue analysis. Their technology leverages intelligence-grade geospatial AI methods to analyze and interpret complex cellular interactions within a patient’s biopsy. This approach moves beyond traditional, static biopsy images to highlight cellular interactions that influence disease progression and treatment response, translating them into actionable insights.
For physicians, Nucleai’s platform, called ATOM, offers an AI-driven spatial biomarker analysis solution that ingests images from various modalities (H&E, IHC, multiplex immunofluorescence, and spatial transcriptomics). It conducts advanced spatial analysis to deliver insights that can optimize biomarker scoring, determine biomarker prevalence and mechanism of action (MoA), and predict response to therapy. This empowers pathologists and researchers with an AI-powered, data-rich action plan, facilitating more informed decisions in the development of next-generation treatments such as bi-specifics, antibody-drug conjugates (ADCs), and immunotherapy. Nucleai’s technology is also being used in clinical settings, including as part of active clinical trials for patient selection.
Focus Areas
Business Intelligence
| Key Investors | M Ventures, Section 32, Sanofi Ventures, Debiopharm Innovation Fund, Fosun RZ Capital, Vertex Ventures Israel, Grove Ventures, S32, Scale Asia Ventures [2, 7, 10, 20] |
| Partnerships | Proscia, GoPath Diagnostics, Lunaphore, Ultivue, Mayo Clinic, University of Glasgow, Sirona Dx [2, 10, 18, 19, 21, 27] |
| Technology | Cloud-native, AI-driven spatial biomarker analysis platform (ATOM), computer vision, deep neural networks, multimodal image analysis (H&E, IHC, multiplex immunofluorescence, spatial transcriptomics) [4, 9, 11, 16] |
What Physicians Need to Know
For physicians, Nucleai's technology offers a deeper, more dynamic understanding of the tumor microenvironment by providing AI-guided spatial maps of patient biopsies. This can lead to better treatment decisions and improved patient care by enabling more precise patient stratification and personalized treatment selection. The platform's ability to analyze complex cellular interactions and predict response to therapy, especially in oncology and immunotherapy, can enhance diagnostic accuracy and inform therapeutic strategies. It can also help identify patients most likely to respond to specific therapies, which is crucial for optimizing clinical trial design and improving the efficacy of new drugs.
Nucleai's platform is agnostic to staining and scanning platforms, offering powerful multiplex analysis capabilities. They are building a global network of academic and clinical institutions and life science tools providers to advance multimodal spatial biology. Notably, Nucleai has partnered with Proscia, a digital pathology company, to integrate Nucleai's predictive biomarker technology into Proscia's Concentriq software platform, aiming to improve clinical trial optimization and treatment decision-making in diagnostic laboratories.
Reviews & Opinions
Videos
News, demos, and interviews about Nucleai.
Videos load interactively. If none appear, search YouTube for Nucleai →
Press & Coverage
Frequently Asked Questions
Investors
Who's funded Nucleai.
Related Companies
QuickIntell is an AI-first healthcare technology company dedicated to transforming healthcare operations for physicians and healthcare providers. The company leverages advanced AI agents, including Computer Vision, Machine Learning, Optical Character Recognition (OCR), and Natural Language Processing (NLP), to streamline administrative workflows and enhance Revenue Cycle Management (RCM). QuickIntell’s solutions are designed to reduce administrative burden, […]
Ease Tax Relief, founded in 2016, is a tax relief and resolution company based in Harleysville, PA. The company specializes in helping individuals and small businesses resolve issues with the IRS, offering services such as Offer in Compromise, Partial Pay Installment Agreements, Payment Plans, and Penalty Reduction. Owned and operated by Zheng Yang, a CPA […]
CAIMed, the Lower Saxony Center for Artificial Intelligence and Causal Methods in Medicine, is a research institution dedicated to advancing personalized healthcare through innovative AI and causal methodologies. The center aims to address widespread diseases such as cancer, cardiovascular diseases, and infections by linking research data, clinical data, and patient care data. This integrated approach, […]
Autoderm is a health technology company that provides a CE-marked AI dermatology screening API designed to analyze smartphone photos for various skin conditions. The company’s AI models are trained on a proprietary database of amateur smartphone images of skin diseases and are accessible via an API that can be integrated into various platforms, including electronic […]
OCTA is an AI-powered finance automation platform that aims to streamline financial operations and accelerate cash flow for businesses, particularly SMEs and enterprises in the Middle East, with a strong presence in the UAE and Saudi Arabia. The platform utilizes AI agents to automate tasks across the entire contract-to-cash cycle, including contract creation, e-signing, invoicing, […]
Skin Analytics is a British health technology company dedicated to the early and accurate diagnosis of skin cancer, aiming to reduce mortality from the disease. They achieve this through their flagship product, DERM, an AI-powered medical device. DERM is designed to provide dermatologist-quality skin cancer assessments, making them more accessible and reducing the burden on […]